December 21, 2017 05:19 PM EST
R&D
Pharma

J&J wows with a $350M cash deal to part­ner on CAR-T with Leg­end, a one-time un­known un­til its star turn at AS­CO

John Carroll

Editor & Founder

J&J has found its next big can­cer drug. In Chi­na.

The phar­ma gi­ant has agreed to pay $350 mil­lion up­front to part­ner with Leg­end Biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

Gilead part­ners with AI start­up Gen­e­sis Ther­a­peu­tics to make small mol­e­cule drugs

GSK to shut down UK an­tibi­ot­ic fa­cil­i­ty fol­low­ing end of San­doz con­tract

Roche's dual GLP-1/GIP re­sults show promis­ing weight loss, but al­so high rates of vom­it­ing

Roivant un­veils its next deal, hop­ing for TL1A-sized po­ten­tial from a shelved Bay­er lung dis­ease ther­a­py

Adicet fol­lows oth­er cell ther­a­py biotechs in au­toim­mune piv­ot

A service from the Financial Times